Eli Lilly’s Olumiant has achieved its first regulatory approval with a nod from the European Commission to treat moderate-to-severe active rheumatoid arthritis. The decision allows the treatment to be used either as a monotherapy or in combination with methotrexate to treat adult patients with the condition who have responded inadequately or are intolerant to one
GlaxoSmithKline and collaborator, Johnson & Johnson, have filed for approval of RA drug sirukumab in the EU. If the drug gains approval it will compete with Roche’s Actemra, which is currently worth $1.5bn. GSK and J&J’s Janssen Biologics unit are seeking EMA approval for their drug in combination with methotrexate in patients who have failed
Pfizer is seeking approval from the US Food and Drug Administration (FDA) for its Xeljanz tablets to treat moderate-to-severe rheumatoid arthritis (RA) in patients with an inadequate response or intolerance to methotrexate (MTX).
Pfizer are celebrating today after US regulators approved their rheumatoid arthritis drug, Xeljanz, yesterday. The treatment is the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis. The US Food and Drug Administration (FDA) have given the green light to Xeljanz (tofacitinib) 5mg twice-daily for the medication of adults with moderately to severely
Phase II study data on Galapagos’ rheumatoid arthritis drug has caused curiosity within the industry. Last week, the Belgian drug maker revealed statistics from a Phase II study of GLPG0634, which showed that the Janus kinase (JAK)-1 inhibitor reached the primary endpoint of significant improvement in the signs and symptoms of rheumatoid arthritis (RA). The 36-patient
